Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 13/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 13/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.65 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.56 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.56 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.56 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22959885 | 0.92 | OPRD1 (0.77) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL29894293 | 0.92 | OPRD1 (0.77) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL13800801 | 0.91 | OPRD1 (0.61) | OPRD1OPRM1OPRK1 | |
| SCHEMBL8211648 | 0.88 | OPRD1 (0.73) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL8211645 | 0.88 | OPRD1 (0.73) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL5666860 | 0.88 | OPRD1 (0.73) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL27855934 | 0.87 | OPRM1 (0.72) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL30301310 | 0.85 | OPRM1 (0.74) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL8561332 | 0.84 | OPRD1 (0.78) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 | |
| SCHEMBL12220381 | 0.84 | OPRD1 (0.78) | OPRD1OPRM1OPRK1MRGPRX2SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143417-A1 | METHODS OF TREATING PAIN | THE UNIVERSITY OF QUEENSLAND (AU) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143417-A1 | METHODS OF TREATING PAIN | OPRL1, NOS2, NOS3 | OPRD1 7/4885OPRM1 6/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.